Literature DB >> 28556585

Diagnosing endocrine hypertension: a practical approach.

Jun Yang1,2, Jimmy Shen1,2, Peter J Fuller1,2.   

Abstract

Hypertension is a leading cardiovascular risk factor that remains difficult to manage in a large segment of the population. Secondary causes of hypertension, which are amenable to targeted treatment or even cure, may contribute to poor blood pressure control. The most common endocrine cause, primary aldosteronism, requires biochemical screening as there are often no symptoms or signs other than hypertension. Screening tests should be performed after adequate preparation to optimize the results and minimize the confounding effects of diet and medications. Further testing beyond the initial screen generally requires input from specialist units to coordinate confirmatory tests and radiological procedures. Other less common or even rare endocrine causes of hypertension generally present with symptoms and signs of pituitary, adrenal, thyroid or parathyroid dysfunction rather than hypertension per se. Here, we review the endocrine causes of hypertension and provide a practical approach to their diagnosis.
© 2017 Asian Pacific Society of Nephrology.

Entities:  

Keywords:  Cushing's syndrome; endocrine hypertension; pheochromocytoma; primary aldosteronism; subclinical Cushing's

Mesh:

Year:  2017        PMID: 28556585     DOI: 10.1111/nep.13078

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  2 in total

1.  Adrenocorticotropic Hormone Secreting Pheochromocytoma Underlying Glucocorticoid Induced Pheochromocytoma Crisis.

Authors:  Gil A Geva; David J Gross; Haggi Mazeh; Karine Atlan; Iddo Z Ben-Dov; Matan Fischer
Journal:  Case Rep Endocrinol       Date:  2018-02-20

2.  Cardiovascular Endocrinology: Evolving Concepts and Updated Epidemiology of Relevant Diseases.

Authors:  Fahimeh Varzideh; Urna Kansakar; Stanislovas S Jankauskas; Jessica Gambardella; Gaetano Santulli
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-05       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.